Lonapegsomatropin & SomatropinTrial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Sponsor:

Ascendis Pharma A/S

Code:

NCT07221851

Conditions

Turner Syndrome

Short Stature Homeobox Gene Mutation

Idiopathic Short Stature

Small for Gestational Age at Delivery

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Interventions

Lonapegsomatropin [SKYTROFA®]

Somatropin Pen Injector

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Ascendis Pharma A/S on 2026-08-19.